An interventional study of VISCO360 ab interno canaloplasty surgery and Selective Laser Trabeculoplasty (SLT) in Open-Angle Glaucoma, sponsored by Sight Sciences, Inc.. Terminated at 6 sites in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2025-11-14.
Sponsored by Sight Sciences, Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Glaucoma, Open-Angle by Sight Sciences, Inc. — none open to participants now, 1 under way, none of them phase 3. Glaucoma, Open-Angle · Sight Sciences, Inc..
Among the 10 studies in Glaucoma, Open-Angle by Sight Sciences, Inc., this one is the only one that started in 2017, is one of 7 with no phase, and was the 1st registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.
Browse Glaucoma, Open-Angle studies →None of the 10 studies in Glaucoma, Open-Angle by Sight Sciences, Inc. is open now. The open studies under Glaucoma, Open-Angle, anywhere →
Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 22 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 1 started in 2017.
This study's enrollment of 29 is below the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Median enrollment 25 across the 8 interventional studies, 49 across the 2 observational. Of the 9 that completed or were terminated, 7 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sight Sciences, Inc. is the lead sponsor of 17 studies on the registry; none are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 12 (92%) have results posted.
1 of the studies in Glaucoma, Open-Angle by Sight Sciences, Inc. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06991270Sight Sciences, Inc.OMNI 3.1 Surgical System in Subjects With Primary Open-Angle Glaucoma | 2026-12-01 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Glaucoma, Open-Angle by Sight Sciences, Inc., from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and effectiveness of the Sight Sciences VISCO™360 Viscosurgical System in reducing intraocular pressure (IOP) in adult, pseudophakic subjects with open-angle glaucoma.
This is a randomized study comparing viscodilation with the VISCO360 device to selective laser trabeculoplasty. Subjects with mild to moderate primary open-angle glaucoma undergo IOP-lowering medication washout at baseline and at Month 12. Subjects will be followed through Month 24.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects randomized to this arm will undergo a surgical procedure in which the VISCO360 Viscosurgical System will be used to microcatheterize and viscodilate Schlemm's canal (i.e., canaloplasty).
Device: VISCO360 ab interno canaloplasty surgery
Subjects randomized to this arm will undergo the SLT procedure.
Device: Selective Laser Trabeculoplasty (SLT)
360 degrees of viscodilation of Schlemm's canal
360 degrees of selective laser trabeculoplasty
Mean Change From Baseline in Diurnal IOP at 12 Months (Measured in mm Hg)
The mean of the difference between the baseline DIOP and the 12 month DIOP for each subject. Measurements at baseline and 12 months are following wash-out of glaucoma medication.
Time frame: 12 months
Proportion of Subjects Achieving a ≥ 20% Change in Mean Diurnal IOP at 12 Months
Measurement is performed at 12 months following wash-out of glaucoma medication and is the number of subjects with 12 month DIOP that is at least 20% lower than the baseline DIOP divided by the number of subjects and multiplied by 100.
Time frame: 12 months
Twenty-nine potential subjects provided written informed consent, however only 17 met eligibility criteria and were then randomized and treated.
| Milestone | VISCO360 ab interno canaloplasty surgery | Selective Laser Trabeculoplasty (SLT) |
|---|---|---|
| Started | 7 | 10 |
| Completed | 0 | 0 |
| Not completed | 7 | 10 |
The mean of the difference between the baseline DIOP and the 12 month DIOP for each subject. Measurements at baseline and 12 months are following wash-out of glaucoma medication.
| mm Hg | VISCO360 ab interno canaloplasty surgery | Selective Laser Trabeculoplasty (SLT) |
|---|---|---|
| Mean Change From Baseline in Diurnal IOP at 12 Months (Measured in mm Hg) | -5.2 ± 7.6 | -3.6 ± 3.3 |
Measurement is performed at 12 months following wash-out of glaucoma medication and is the number of subjects with 12 month DIOP that is at least 20% lower than the baseline DIOP divided by the number of subjects and multiplied by 100.
| Participants | VISCO360 ab interno canaloplasty surgery | Selective Laser Trabeculoplasty (SLT) |
|---|---|---|
| Proportion of Subjects Achieving a ≥ 20% Change in Mean Diurnal IOP at 12 Months | 2 | 1 |
Collected over 18 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| VISCO360 ab interno canaloplasty surgery | 1/7 (14.3%) | 1/7 (14.3%) | 1/7 (14.3%) |
| Selective Laser Trabeculoplasty (SLT) | 0/10 (0%) | 2/10 (20%) | 4/10 (40%) |
| Event | VISCO360 ab interno canaloplasty surgery | Selective Laser Trabeculoplasty (SLT) |
|---|---|---|
| non-ocularCardiac disorders | 1/7 | 0/10 |
| Ocular adverse eventEye disorders | 0/7 | 1/10 |
| non-ocularCardiac disorders | 0/7 | 1/10 |
| Event | VISCO360 ab interno canaloplasty surgery | Selective Laser Trabeculoplasty (SLT) |
|---|---|---|
| Ocular adverse eventsEye disorders | 1/7 | 0/10 |
| ocular adverse eventEye disorders | 0/7 | 1/10 |
| non-ocular adverse eventRespiratory, thoracic and mediastinal disorders | 0/7 | 1/10 |
| non ocular adverse eventGeneral disorders | 0/7 | 1/10 |
| ocular adverse eventEye disorders | 0/7 | 1/10 |
| ocular adverse eventEye disorders | 0/7 | 1/10 |
| non ocular adverse eventGeneral disorders | 0/7 | 1/10 |
| Age, Continuous(years) | VISCO360 ab Interno Canaloplasty Surgery | Selective Laser Trabeculoplasty (SLT) | Total |
|---|---|---|---|
| Mean | 76.1 ± 6.7 | 74.7 ± 11.5 | 75.4 ± 9.1 |
| Sex: Female, Male(Participants) | VISCO360 ab Interno Canaloplasty Surgery | Selective Laser Trabeculoplasty (SLT) | Total |
|---|---|---|---|
| Female | 3 | 6 | 9 |
| Male | 4 | 4 | 8 |
| Ethnicity (NIH/OMB)(Participants) | VISCO360 ab Interno Canaloplasty Surgery | Selective Laser Trabeculoplasty (SLT) | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 2 | 5 |
| Not Hispanic or Latino | 4 | 8 | 12 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | VISCO360 ab Interno Canaloplasty Surgery | Selective Laser Trabeculoplasty (SLT) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 |
| White | 3 | 8 | 11 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 3 | 2 | 5 |
| Region of Enrollment(Participants) | VISCO360 ab Interno Canaloplasty Surgery | Selective Laser Trabeculoplasty (SLT) | Total |
|---|---|---|---|
| United States | 7 | 10 | 17 |
| Diurnal Intraocular Pressure(mm Hg) | VISCO360 ab Interno Canaloplasty Surgery | Selective Laser Trabeculoplasty (SLT) | Total |
|---|---|---|---|
| Mean | 25.8 ± 4.3 | 25.1 ± 2.5 | 25.4 ± 3.2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2017 to primary completion in Jan 2019, 23 months.
Results were first posted in Sep 2025, 6 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sight Sciences, Inc.